Sort   by:  
 Page size 
UnknownEngineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation.
Not available
S-EPMC11999459 | biostudies-literature
UnknownOH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via β-catenin pathway suppression.
Not available
S-EPMC12304221 | biostudies-literature
ProteomicsOH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via β-catenin pathway suppression
The five-year survival rate for non-small-cell lung cancer (NSCLC) remains poor, primarily due to tumor invasion and metastasis. This study evaluates the anti-metastatic potential of the oncolytic virus OH2 in NSCLC. OH2 inhibits migration and invasion of NSCLC by downregulating β-catenin, as demons...
ORGANISM(S): Homo sapiens (Human) 
2025-07-27 | PXD065329 | Pride
Oncolytic virotherapy  metastasis inhibition  herpes simplex virus  beta-catenin  non-small cell lung cancer 
UnknownTerminal NiII-OH/-OH2 complexes in trigonal bipyramidal geometries derived from H2O.
Not available
S-EPMC5695699 | biostudies-literature
TranscriptomicsTreatment of prostate cancer with oncolytic virus OH2 [bulkRNA-seq_tumors]
Prostate cancer is a major challenge due to limited treatment options in advanced stages. Immunotherapy has shown promising prospects in various cancers, but it faces obstacles in prostate cancer due to its immunosuppressive microenvironment and low response rate to current therapies. Oncolytic viru...
ORGANISM(S): Mus musculus 
2025-08-30 | GSE298912 | GEO
TranscriptomicsTreatment of prostate cancer with oncolytic virus OH2 [bulkRNA-seq_22-Rv1]
Prostate cancer is a major challenge due to limited treatment options in advanced stages. Immunotherapy has shown promising prospects in various cancers, but it faces obstacles in prostate cancer due to its immunosuppressive microenvironment and low response rate to current therapies. Oncolytic viru...
ORGANISM(S): Homo sapiens 
2025-09-01 | GSE298914 | GEO
TranscriptomicsTreatment of prostate cancer with oncolytic virus OH2 [bulkRNA-seq_C4-2]
Prostate cancer is a major challenge due to limited treatment options in advanced stages. Immunotherapy has shown promising prospects in various cancers, but it faces obstacles in prostate cancer due to its immunosuppressive microenvironment and low response rate to current therapies. Oncolytic viru...
ORGANISM(S): Homo sapiens 
2025-09-01 | GSE298913 | GEO
TranscriptomicsTreatment of prostate cancer with oncolytic virus OH2 [scRNA-seq_RM-1]
Prostate cancer is a major challenge due to limited treatment options in advanced stages. Immunotherapy has shown promising prospects in various cancers, but it faces obstacles in prostate cancer due to its immunosuppressive microenvironment and low response rate to current therapies. Oncolytic viru...
ORGANISM(S): Mus musculus 
2025-09-01 | GSE298915 | GEO
UnknownIntratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial.
Not available
S-EPMC11748782 | biostudies-literature
UnknownSIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment.
Not available
S-EPMC9620659 | biostudies-literature
Sort   by:  
 Page size